Qualigen Therapeutics, Inc. (NASDAQ:QLGN – Get Free Report) shares traded up 2.3% during mid-day trading on Tuesday . The stock traded as high as $1.39 and last traded at $1.36. 44,803 shares changed hands during trading, a decline of 96% from the average session volume of 1,029,491 shares. The stock had previously closed at $1.33.
Qualigen Therapeutics Stock Performance
The stock’s fifty day moving average price is $1.26 and its two-hundred day moving average price is $2.38. The company has a market cap of $2.31 million, a P/E ratio of -0.18 and a beta of 0.24.
Qualigen Therapeutics Company Profile
Qualigen Therapeutics, Inc (NASDAQ: QLGN) is a life sciences company headquartered in Westminster, Colorado, that combines immunodiagnostic reagents with novel immuno-oncology therapies. Operating through two primary business units—Qualigen Diagnostic Solutions and Qualigen BioTherapeutics—the company seeks to leverage its expertise in antibody engineering and assay development to address both clinical laboratory needs and unmet medical needs in oncology.
Through its Qualigen Diagnostic Solutions division, the company designs, manufactures and distributes immunoassay reagents, kits and related consumables for use in clinical and research laboratories.
Featured Articles
Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
